
TRPX
Healthcare · Biotechnology · $4.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2020 | Time not confirmed | 0.00 | -14.00 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -14.00 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -13.55 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -13.55 | — |
| Feb 27, 2019 | Time not confirmed | — | -1.00 | — |
| Dec 31, 2018 | Time not confirmed | — | -53.41 | — |
| Sep 30, 2018 | Time not confirmed | -41.30 | -38.95 | +5.7% |
| Apr 30, 2018 | After the close | -35.70 | -58.10 | -62.7% |
| Feb 28, 2018 | Time not confirmed | -0.51 | -0.41 | +19.6% |
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the…